Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Tumor Boards
Colleague Insights
Living Resources
Conferences
Video Expert Opinion
Round Table Discussions
Sign in
Join now

In an effort to better serve our users, we have streamlined our content offering. As a result, we no longer publish new content or update existing content in Advanced Prostate Cancer. Visit the 'Content & Subscriptions' tab of your Settings page at any time to update your Dashboard or Newsletter Subscription preferences to continue to see news and information that interests you most.

featured
Published in Advanced Prostate Cancer

Expert Opinion / Cases · May 25, 2022

59-Year-Old Man With mCRPC Presenting for Second Opinion

Pedro Barata MD

 

 Save  Recommend
 Share

Discuss This item Follow

No comments yet, be the first to start the discussion!

  • mohamed lemine sow

    May 26, 2022

    AS a radiologique biologique progression ECOG1,i will start abiraterone acetate plus prednisone

  • Ismail Abdelhafeez

    May 26, 2022

    Start Docetaxel

  • deepak  dabkara

    May 26, 2022

    I will opt for docetaxel. 15 months response to Adt and enzalutamide can not be considered a very good response. Patient has psa and radiological progression. Very unlikely that he will respond to AA- Pred

  • deepak  dabkara

    May 26, 2022

    I will opt for docetaxel. 15 months response to Adt and enzalutamide can not be considered a very good response. Patient has psa and radiological progression. Very unlikely that he will respond to AA- Pred

  • Eman Ahmed

    May 26, 2022

    2. Remaining on enzalutamide and add Radium223

  • Juan Artigas

    May 26, 2022

    Remain in enzalutamide and add Docetaxel

  • Charles Maack

    May 26, 2022

    start docetaxel 75 mg/m2

  • leo badinez

    May 29, 2022

    sbrt and evaluate psa response

  • HUGO OTAOLA ARCA

    May 29, 2022

    Start docetaxel

  • Manuel Ossa

    May 31, 2022

    Starts Docetaxel

  • Vladimira Stahalova

    Jun 29, 2022

    start docetaxel 75 mg/m2

  • Jan 18, 2025

    Pending Moderator approval.
    Delete

Further Reading

Recently Updated